Marshall Edwards initiates trial of chemo-sensitizer
1st Dec 2005, 02:24 GMT
Marshall Edwards and Sanofi-Aventis are jointly supporting a phase Ib/IIa study of the investigational anticancer drug phenoxodiol in combination with docetaxel for women with recurrent ovarian cancer.
Marshall Edwards initiates trial of chemo-sensitizer related news:
- New Clinical Study of Phenoxodiol as Chemo-sensitizer for Docetaxel in Ovarian Cancer Commences at Yale University School of Medicine — PR Newswire: All Releases
- New Clinical Study of Phenoxodiol as Chemo-sensitizer for Docetaxel in Ovarian Cancer Commences at Yale Univ School of Medicine — Operations-Related News from StratCenter.com
- Lawyer says Fieger partner told him to contribute to Edwards — JournalNow News Updates
- Lawyer says firm demanded political contributions to Edwards — www.heraldsun.com
- Marshall comes up big at end for Cavs — HeraldTimesOnline.com
- Marshall lifts Cavs over Clips in OT (AP) — Yahoo! Sports - NBA News
- Anormed initiates trial of novel HIV inhibitor — Pharmaceutical Business Review Online
- Aastrom initiates spinal bone formation trial — Pharmaceutical Business Review Online
- Knee injury could end Edwards' season — FOXSports.com News for NFL
- Provectus initiates phase I trial in breast cancer — Pharmaceutical Business Review Online
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol